___

• Beer S, Rosler KM, Hess CW. Diagnostic value of para- clinical tests in multiple sclerosis: relative sensitivities and specifities for reclassification according to the Poser Committee criteria. J Neurol Neurosurg Psychiatry 1995; 59:152-9.
• Bednarik J, Kadanka Z. Multimodal sensory and motor evoked potentials in a two-year follow-up study of MS pa- tients with relapsing course. Acta Neurol Scand 1992; 86:15-8.
• Kurtzke J. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
• Iragui VJ, Wiederholt WC, Romine JS. Serial recordings of multimodality evoked potentials in multiple sclerosis. Can J Neurol Sci 1986;13: 320-6.
• Anderson DC, Slater GE, Sherman R, Ettinger MG. Evoked potentials to test a treatment of chronic multiple sclero- sis. Arch Neurol 1987;44:1232-6.
• Isaac C, Li DK, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988;38: 1511-5.
• Sater RA, Rostami AM, Galetta S, Farber RE, Bird SJ. Serial evoked potential studies and MRI imaging in chronic pro- gressive multiple sclerosis. J Neurol Sci 1999;171: 79–83.
• Eikelenboom MJ, Killestein J, Uitdehaag BMJ, CH Polman CH. Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis. Multiple Sclerosis 2005;11:520-3.
• Charlton B, Lafferty KJ. The Th1/Th2 balance in autoim- munity. Curr Opin Immunol 1995;7:793-8.
• Uhlenbrock D, Seidel D, Gehlen W, et al. MR imaging in multiple sclerosis: comparison with clinical, CSF and vi- sual evoked potential findings. AJNR 1988;9:59-67.
• Gareau PJ, Gati JS, Menon RS, et al. Reduced visual evoked responses in multiple sclerosis patients with optic neuritis: Comparison of functional magnetic resonance imaging and visual evoked potentials. Multiple Sclerosis 1999;5;161-4.
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for MS: Guidelines from the interna- tional Panel on the diagnostic of MS. Ann Neurology 2001; 50: 121-7.
• Skurkovich S,Boiko A, Beliaeva A, et al. Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis. Multiple Sclerosis 2001;7:277-84.
• Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple scle- rosis: from bench to bedside. Pharmacology Theraputics 2005;106:163-77.
• Liu J, Marino MW, Wong G, et al. TNF is a potent anti- inflammatory cytokine in autoimmune-mediated demy- elination. Nat Med 1998;4:78– 83.
• Hellings N, Raus J, Stinissen P. Insights into the immu- nopathogenesis of multiple sclerosis. Immunol Res 2002; 25:27–51.
• Hautecoeour P, Forzy G, Gallois P, Demirbilek V, Feagas O. Variations of Il-2, IL-6 and TNF- plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol Belg 1997;97:240-3.
• Anlar O, Kıslı M, Tombul T, Ozbek H. Visual evoked poten- tials in multiple sclerosis before and after two years of interferon therapy. Int J Neuroscience 2003;113: 483-9.
• Khoury SJ, Weiner HL. Multiple sclerosis. What have we learned from magnetic resonance imaging studies? Arch Intern Med 1998;158: 565-73.
• Comi G, Filippi M, Rovaris M, Leocani L, Medaglini S, Locatelli T. Clinical, neurophysiological, and magnetic resonance imaging correlations in multiple sclerosis. J Neurol Neurosurg Psychiatry Suppl 1, 1998;64:21–5.
• Paty DW, McFarland H. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pa- thology and to monitor definitive clinical trials. J Neurol Neurosurg Psychiatry, Suppl 1, 1998; 64: 47–51.
• Fillipi M, Mastronardo G, Bastianello S, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow up study. Neurology 1995; 45: 255-260.
• Truyen L, van Waerberghe JH, van Walderveen MA, et al. Accumulation of hypotense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in mul- tiple sclerosis. Neurology 1996;47:1469-76.
• Miller DH, Grosmann RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121:3-24.
• O’Conner P, Marchetti P, Lee L, Perera M. Evoked poten- tial abnormality scores are useful measure of disease bur- den in relapsing-remitting multiple sclerosis. Ann Neurol 1998;44: 404-7.
• Fuhr P, Kappos L. Evoked potentials for evaluation of mul- tiple sclerosis. Clin Neurophysio, 2001;112: 2185–9.
• Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and motor evoked potentials in the course of mul- tiple sclerosis. Brain 2001;124: 2162-8.